<?xml version="1.0" encoding="UTF-8"?>
<p id="Par105">To improve the diversity of products and generate better antibody drugs, major development efforts have yielded models, such as the fully human antibody mouse and second-generation chimeric human antibody mice, over the 30â€‰years since the first transgenic mouse was generated in 1989 [
 <xref ref-type="bibr" rid="CR167">167</xref>]. The continued refinement and advancement of transgenic animals provides ever more possibilities for antibody drug development by global pharmaceutical factories.
</p>
